Patent ID: 7022705

Claim:
A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring consisting of 3 nitrogen atoms, which ring is optionally substituted on a C atom, other than a C atom adjacent to the linking N atom, by an oxo or thioxo group; and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by a substituent Rs wherein; Rs is halogen, (1–4C)alkoxy, (2–4C)alkenyloxy, (2–4C)alkenyl, (2–4C)alkynyl, (3–6C)cycloalkyl, (3–6C)cycloalkenyl, amino, (1–4C)alkylamino, di-(1–4C)alkylamino, (2–4C)alkenylamino, (1–4C)alkylcarbonylamino, (1–4C)alkylthiocarbonylamino, (1–4C)alkyl-OCO—NH—, (1–4C)alkyl-NH—CO—NH—, (1–4C)alkyl-NH—CS—NH—, (1–4C)alkyl-SO 2 —NH— or (1–4C)alkyl-S(O)q— (wherein q is 0, 1 or 2); fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, bromomethyl, cyanomethyl, cyano, amino, azido or methylthiomethyl; Q is:— wherein R 2 and R 3 are independently hydrogen or fluoro; wherein T is (TCc) an optionally substituted 6-membered monocyclic ring consisting of 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom or a ring sp 1 or sp 2 carbon atom, which monocyclic ring is fully saturated other than (where appropriate) at a linking sp 2 carbon atom.